The ECOG-ACRIN Cancer Research Group presented data from PROSPER RCC (EA8143), the first randomized phase III trial of neoadjuvant immunotherapy in patients with kidney cancer, at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA67). Patients with high-risk renal cell carcinoma (RCC) were randomly assigned in an open-label design to undergo surgery alone, or an approach of priming the immune system with nivolumab prior to full or partial removal of the kidney followed by additional nivolumab—an approach strongly supported by patient advocates. At a planned interim analysis, the trial showed no difference in recurrence-free survival between arms in a population of patients that included both clear cell and non–clear cell disease subtypes; as such, the study was stopped early.
The trial’s Urology Chair Mohamad E. Allaf, MD, of Johns Hopkins Medicine, presented the late-breaking data on September 10 during the Congress.
“Perioperative nivolumab did not improve recurrence-free survival in patients with renal cell carcinoma and at high risk for recurrence,” said Dr. Allaf. “Ongoing radiomic, pathomic, and other biomarker analyses within this trial may inform the design of future neoadjuvant trials in this disease.”
He continued: “Patients with seemingly localized kidney cancer currently have surgery with observation as the standard of care; however, up to a third of these patients will experience disease recurrence, and their fate then is that of patients with metastatic disease.”
“The PROSPER-RCC trial took the unique approach of giving immunotherapy before surgery when the tumor was in place, and all of the immune cells had close interaction with the agent, such that it could potentially stimulate a response,” said ECOG-ACRIN Genitourinary Committee Co-Chair Naomi B. Haas, MD, a medical oncologist at Penn Medicine’s Abramson Cancer Center in Philadelphia, and senior author of the study.
With the increased use of imaging over the past several decades, RCC is being detected at earlier stages when it is potentially more curable. Surgery with observation is the standard of care for patients with localized disease. However, despite nephrectomy, many patients recur, and for them, a subsequent cure is unlikely.
“Given the lack of cure with the available agents in the advanced setting, the PROSPER RCC trial explored whether targeting microscopic disease in the perioperative setting is rational,” said Dr. Haas. “The results of this trial are not enough to impact clinical practice at this time. We await the [results from the] ongoing CheckMate-914 trial of postoperative nivolumab with interest, as well as the data from other RCC trials being reported here at ESMO Congress 2022.”
PROSPER RCC Details
PROSPER RCC enrolled patients with either clear cell subtype (the most common) or non–clear cell RCC. Between February 2017 and June 2021, 819 patients were randomly assigned to receive perioperative nivolumab (n = 404) or surgery alone (n = 415). Following a planned interim analysis, the trial was stopped early by the ECOG-ACRIN Data Safety Monitoring Committee in March 2022 due to futility. Recurrence-free survival was similar between the arms (hazard ratio [HR] = 0.97, 95% confidence interval [CI] = 0.74– 1.28, 1-sided P = .43). The median recurrence-free survival was not reached.
Adverse events were more common in the nivolumab arm but were consistent with what is expected for nivolumab immunotherapy. Among patients treated with nivolumab, 20% experienced at least one grade 3 or 4 adverse event that could be attributable to nivolumab, compared with 6% in the control arm.
Overall survival was not mature at the time of analysis. Subset analyses by pathologic stage are ongoing.
Disclosure: ECOG-ACRIN designed and conducted the PROSPER RCC trial with primary funding support from the National Cancer Institute (NCI) through the NCI National Clinical Trials Network. ECOG-ACRIN received additional funding support from Bristol Myers Squibb, the manufacturer of nivolumab. The NCI is sponsoring the trial under its clinical collaborative agreement with Bristol Myers Squibb for nivolumab. For full disclosures of the study authors, visit oncologypro.esmo.org.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.